These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 24516633)

  • 1. Gene co-expression modules as clinically relevant hallmarks of breast cancer diversity.
    Wolf DM; Lenburg ME; Yau C; Boudreau A; van 't Veer LJ
    PLoS One; 2014; 9(2):e88309. PubMed ID: 24516633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer.
    Amara D; Wolf DM; van 't Veer L; Esserman L; Campbell M; Yau C
    Breast Cancer Res Treat; 2017 Jan; 161(1):41-50. PubMed ID: 27815749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlating transcriptional networks with pathological complete response following neoadjuvant chemotherapy for breast cancer.
    Liu R; Lv QL; Yu J; Hu L; Zhang LH; Cheng Y; Zhou HH
    Breast Cancer Res Treat; 2015 Jun; 151(3):607-18. PubMed ID: 25981901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-expression module analysis reveals biological processes, genomic gain, and regulatory mechanisms associated with breast cancer progression.
    Shi Z; Derow CK; Zhang B
    BMC Syst Biol; 2010 May; 4():74. PubMed ID: 20507583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The gene expression landscape of breast cancer is shaped by tumor protein p53 status and epithelial-mesenchymal transition.
    Fredlund E; Staaf J; Rantala JK; Kallioniemi O; Borg A; Ringnér M
    Breast Cancer Res; 2012 Jul; 14(4):R113. PubMed ID: 22839103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of breast cancer prognostic modules via differential module selection based on weighted gene Co-expression network analysis.
    Guo L; Mao L; Lu W; Yang J
    Biosystems; 2021 Jan; 199():104317. PubMed ID: 33279569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of key gene modules and pathways of human breast cancer by co-expression analysis.
    Zhao Q; Song W; He DY; Li Y
    Breast Cancer; 2018 Mar; 25(2):213-223. PubMed ID: 29170883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel module and hub genes of distinctive breast cancer associated fibroblasts identified by weighted gene co-expression network analysis.
    Xu Y; Zhang Z; Zhang L; Zhang C
    Breast Cancer; 2020 Sep; 27(5):1017-1028. PubMed ID: 32383139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Denoising perturbation signatures reveal an actionable AKT-signaling gene module underlying a poor clinical outcome in endocrine-treated ER+ breast cancer.
    Teschendorff AE; Li L; Yang Z
    Genome Biol; 2015 Apr; 16(1):61. PubMed ID: 25886003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of key tumor stroma-associated transcriptional signatures correlated with survival prognosis and tumor progression in breast cancer.
    Uddin MN; Wang X
    Breast Cancer; 2022 May; 29(3):541-561. PubMed ID: 35020130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures.
    Wirapati P; Sotiriou C; Kunkel S; Farmer P; Pradervand S; Haibe-Kains B; Desmedt C; Ignatiadis M; Sengstag T; Schütz F; Goldstein DR; Piccart M; Delorenzi M
    Breast Cancer Res; 2008; 10(4):R65. PubMed ID: 18662380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of co-expression modules and potential biomarkers of breast cancer by WGCNA.
    Jia R; Zhao H; Jia M
    Gene; 2020 Aug; 750():144757. PubMed ID: 32387385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-expression network analysis identified candidate biomarkers in association with progression and prognosis of breast cancer.
    Zhou Q; Ren J; Hou J; Wang G; Ju L; Xiao Y; Gong Y
    J Cancer Res Clin Oncol; 2019 Sep; 145(9):2383-2396. PubMed ID: 31280346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.
    Bastien RR; Rodríguez-Lescure Á; Ebbert MT; Prat A; Munárriz B; Rowe L; Miller P; Ruiz-Borrego M; Anderson D; Lyons B; Álvarez I; Dowell T; Wall D; Seguí MÁ; Barley L; Boucher KM; Alba E; Pappas L; Davis CA; Aranda I; Fauron C; Stijleman IJ; Palacios J; Antón A; Carrasco E; Caballero R; Ellis MJ; Nielsen TO; Perou CM; Astill M; Bernard PS; Martín M
    BMC Med Genomics; 2012 Oct; 5():44. PubMed ID: 23035882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures.
    Karn T; Pusztai L; Holtrich U; Iwamoto T; Shiang CY; Schmidt M; Müller V; Solbach C; Gaetje R; Hanker L; Ahr A; Liedtke C; Ruckhäberle E; Kaufmann M; Rody A
    PLoS One; 2011; 6(12):e28403. PubMed ID: 22220191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A favorable role of prolactin in human breast cancer reveals novel pathway-based gene signatures indicative of tumor differentiation and favorable patient outcome.
    Hachim IY; Shams A; Lebrun JJ; Ali S
    Hum Pathol; 2016 Jul; 53():142-52. PubMed ID: 26980025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene modules associated with breast cancer distant metastasis-free survival in the PAM50 molecular subtypes.
    Liu R; Zhang W; Liu ZQ; Zhou HH
    Oncotarget; 2016 Apr; 7(16):21686-98. PubMed ID: 26934123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer.
    Reyal F; van Vliet MH; Armstrong NJ; Horlings HM; de Visser KE; Kok M; Teschendorff AE; Mook S; van 't Veer L; Caldas C; Salmon RJ; van de Vijver MJ; Wessels LF
    Breast Cancer Res; 2008; 10(6):R93. PubMed ID: 19014521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Network-based approach to identify prognostic biomarkers for estrogen receptor-positive breast cancer treatment with tamoxifen.
    Liu R; Guo CX; Zhou HH
    Cancer Biol Ther; 2015; 16(2):317-24. PubMed ID: 25756514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups.
    Netanely D; Avraham A; Ben-Baruch A; Evron E; Shamir R
    Breast Cancer Res; 2016 Jul; 18(1):74. PubMed ID: 27386846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.